<DOC>
	<DOCNO>NCT00074841</DOCNO>
	<brief_summary>This primary objective study ass whether combination Azithromycin chloroquine non-inferior combination sulfadoxine-pyrimethamine plus chloroquine , use treat uncomplicated case malaria due Plasmodium falciparum adult India .</brief_summary>
	<brief_title>Trial Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine Treatment Uncomplicated Malaria India</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<criteria>INCLUSION CRITERIA : Females male &gt; =18 year age uncomplicated , symptomatic malaria indicate presence following : . ) Blood smear positive Plasmodium falciparum asexual parasitemia 1000 100,000 parasites/uL ; b . ) Fever history fever ( &gt; =38.5C/101.2F rectal tympanic ; &gt; =37.5C/99.5F axillary &gt; =38C/100.4F oral ) within prior 24 hour Serum glucose &gt; = 60 mg/dL ( fingerstick peripheral blood collection ) Positive rapid diagnostic test ( Binax NOW ICT ) positive P. falciparum Women childbearing potential must negative urine gonadotropin prior entry study must agree use adequate contraception entire study EXCLUSION CRITERIA : Severe complicate malaria include subject follow : . ) Impaired consciousness ( e.g . obtundation , unarousable coma ) , seizures abnormal neurologic exam suggestive severe complicate malaria ; b . ) Hemoglobinuria ; c. ) Jaundice ; d. ) Respiratory distress ( respiratory rate &gt; =30/min ) ; e. ) Persistent vomit ; f. ) Hematuria , report patient Pregnant breastfeed woman History allergy hypersensitivity azithromycin macrolide , sulfonamide , pyrimethamine , chloroquine Known suspect folate deficiency Known history blood dyscrasia ( e.g. , megaloblastic anemia , agranulocytosis , aplastic anemia , thrombocytopenia , leukopenia , neutropenia , hemolytic anemia ) Known G6PD deficiency History epilepsy psoriasis History treatment antimalarial drug ( chloroquine , quinine , mefloquine , Malarone , SP , artemisinin compound ) antibacterial know antimalarial activity ( macrolides , doxycycline , clindamycin ) within 2 week prior enrollment study Known suspect cardiovascular , hepatic renal abnormality opinion Investigator would place subject increase risk participate study . The following finding specific exclusion : . ) Serum creatinine &gt; 2.0 x ULN ; b . ) ALT and/or AST &gt; 3 x ULN Inability swallow oral medication tablet form Treatment investigational drug within 30 day prior enrollment study Alcohol and/or drug abuse Requirement use medication study might interfere evaluation study drug Specific systemic disease medical condition would interfere evaluation therapeutic response safety study drug Inability comprehend and/or unwillingness follow study protocol Prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>MALARIA</keyword>
	<keyword>INDIA</keyword>
	<keyword>CHLOROQUINE</keyword>
	<keyword>PLASMODIUM FALCIPARUM</keyword>
	<keyword>SULFADOXINE-PYRIMETHAMINE</keyword>
</DOC>